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COURT OF APPEALS, 1961 TERM
EDUCATION LAW
BAYER ASPIRIN TABLETS HELD To BE A PROPRIETARY MEDICINE WITHIN THE
EXCEPTION TO THE NEW YORK EDUCATION LAW
Appellant, a New York corporation, has been selling pre-packaged Bayer
Aspirin Tablets since 1950.1 In January, 1955, appellants were charged with
violating the State Education Law for selling these aspirin tablets. After
discontinuing the sale of Bayer Aspirin, appellants brought this action for a
declaratory judgment, establishing their right to continue the sale of these
tablets without first obtaining registration certificates from the Board of Phar-
macy, and further establishing that its employees have the right to make such
sales. In addition, a permanent injunction was requested to restrain the defend-
ants from interfering with the sale of Bayer Aspirin by way of section 6823(2)
of the Education Law.2 While the Supreme Court granted summary judgment
for the plaintiff,3 the Appellate Division reversed that judgment and directed
a verdict for defendants. 4 In the Court of Appeals, held, reversed, all concurring,
that under these circumstances, Bayer Aspirin, prepared with inert elements
and by secret, complicated processes of manufacture, producing individual
qualities differing in some degree from those tablets processed by other com-
panies, were "proprietary medicines" within the statute exempting these
medicines from the requirement that drugs be sold in licensed pharmacies. This
was held although the active ingredients were known and patents had expired.
Loblaw, Inc. v. New York State Board of Pharmacy, 11 N.Y.2d 102, 181
N.E.2d 621, 226 N.Y.S.2d 681 (1962).
There are two definitions which have been used in determining what is a
proprietary medicine. The first of these is called the "common usage" definition
and has five requirements: (1) the producer must have an existing property
right, (2) this right may be attributed to a patent, trademark, special formula
or unique process for preparation, (3) it must be a pre-packaged medicine
in fully prepared form ready for use by the consumer with adequate directions
for such use, (4) it must be extensively advertised by the brand name, and (5)
no prescription is needed.5 A further requirement is needed if the technical or
second definition is to be complied with, that is, the existence of a secret
process of manufacture.6
The issue in this case was whether or not Bayer tablets were an exempt
1. Loblaw, Inc., operates 228 supermarkets in New York, Pennsylvania, Ohio, and
West Virginia, of which 141 are located in New York State.
2. N.Y. Educ. Law § 6823(2) provides for a fine to be assessed against any violator
of this article who is not criminally prosecuted on the complaint of the board as for a.
misdemeanor, and the procedure for such assessment.
3. 22 Misc. 2d 131, 202 N.Y.S.2d 711 (Sup. Ct. 1960).
4. 12 A.D.2d 180, 210 N.Y.S.2d 709 (4th Dep't 1961).
5. Wrigley's Stores v. Michigan Board of Pharmacy, 336 Mich. 583, 59 N.W.2d 8
(1953).
6. Loblaw, Inc. v. New York State Board of Pharmacy, 11 N.Y.2d 102, 109, 181
N.E.2d 621, 623, 226 N.Y.S.2d 681, 685 (1962).
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proprietary medicine under the State Education Law.7 This Court affirms the
decision of Special Term and reverses the Appellate Division, stating that
the Appellate Division holding went beyond either of the above-stated definitions
and denied the existence of a proprietary right, without regard to the owner-
ship of trademarks or secret processes of manufacture, if it is shown that the
basic and essential elements were known to and freely used by the public.
The New York Pharmaceutical Society, as amicus curiae, urged that these
tablets are a proprietary remedy on the basis of the holding in Bayer Co., Inc.
v. United Drug Co.8 They argued that that case dealt with what constitutes a
proprietary remedy, while the Court here held that this issue was not before
the Bayer Co. court which decided only questions of trademarks and fair compe-
tition.
The criteria followed by the Michigan court and used by this Court, when
supplemented by the stated policy considerations, reveal the true reasons for
the Court's holding-that Bayer tablets are proprietary medicines within the
statutory exemption. Judge Van Voorhis, in consideration of the purpose
behind the statute, states that "limiting the sale of such medicines to pharma-
cists or drug stores would furnish no protection to the public without some
further mandatory direction as to inspection or analysis by the pharmacists
or druggist which would tend to exclude from sale medicines that might be injuri-
ous to health, or some requirement to exercise their skill and science in determining
the quality and properties of such as they sell" (citation omitted).1° If the
Court had limited the sale here, the market would have been greatly restricted,
which is a result seldom reached unnecessarily by a Court well aware of the
established policy favoring free competition. Agreeing with Special Term, the
Court said, "it is common knowledge that most drug stores are engaged in a
wide field of merchandising having no connection with drugs, and that no pro-
fessional judgment or discrimination is required or used in making sales of
Bayer Aspirin Tablets."" Here the two basic reasons for the decision are seen,
in that Bayer Aspirin Tablets could be found to be a proprietary medicine
under the criteria used by the Court, and secondly, that there is no reason to
distinguish drug stores and supermarkets in the sale of Bayer Aspirin since
they are sold in the same manner.
Drug stores and supermarkets have become engaged in a competitive battle
in recent years which has been due to their efforts to seek a larger market. Now
that this battle has reached the courtrooms, it seems likely that similar litiga-
tion will flourish. It is interesting to note that in view of this competition, plus
7. N.Y. Educ. Law § 6816(2): "Except as to the labeling of poison and to adulterating,
misbranding and substituting, it (Art. 137) shall not apply; .. . c. to the sale of pro-
prietary medicines except those proprietary medicines which are poisonous, deleterious
and/or habit forming."
8. 272 Fed. 505 (S.D.N.Y. 1921).
9. Wrigley's Stores, supra note S.
10. Loblaw, Inc., supra note 6, at 111, 181 N.E.2d at 625, 226 N.Y.S.2d at 686.
11. Loblaw, Inc., supra note 6, at 113, 181 N.E.2d at 626, 226 N.Y.S.2d at 689.
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the absence of any definitive framework concerning proprietary medicines
in New York, the Court of Appeals specifically declined to base their holding
upon more definite grounds, including an all-inclusive definition of proprietary
medicines, in order to limit the necessity of future litigation in this area. This
statute is a health measure enacted under the police powers of the state. While
such a measure should not be a mere pretext to confer upon one group a competi-
tive advantage, this consideration enters primarily into the constitutionality of
the statute, i.e., whether or not there is a reasonable relation to public health.12
While the Court undoubtedly reaches the right result, and furnishes some
authority for future litigation, the opinion introduces another indefinite ele-
ment-economic considerations-into the issue, where the issue itself is not
delimited by a clear New York rule.
B.B.F.
REVOCATION OF PYSIciAN'S LICENSE FOR DECEIT IN REPORTS TO THIRD
PARTI S
The appellant was found guilty of fraud and deceit in the practice of
medicine and of unprofessional conduct after a formal hearing before a sub-
committee of the Medical Committee on Grievances. He was charged with
submitting false and exaggerated medical reports and bills to an attorney, to
insurance companies, and to the Transit Authority. The findings of fact were
supported by substantial documentary evidence and testimony. The evidence
also tended to show that such acts continued until 1956. The Medical Com-
mittee on Grievances confirmed such findings with all nine members present
voting guilty, and appellant's license to practice medicine was revoked. This
determinati6n was unanimously confirmed by the Appellate Division. On ap-
peal, held, affirmed. Nothing in the statute under which appellant was found
guilty limits discipline to cases where the fraud is perpetrated directly on the
patient. Where the fraud is practiced on anyone and it affects a public interest,
the physican is subject to discipline. A unanimous vote of the Grievance Com-
mittee, where a quorum is present, is sufficient to find a physician guilty. Was-
sermann v. Board of Regents, 11 N.Y.2d 173, 182 N.E.2d 264, 227 N.Y.S.2d
649 (1962).'
A physician may have his license revoked or suspended when found
"guilty of fraud or deceit in the practice of medicine"2 or when the "physician
is or has been guilty of unprofessional conduct." 3 The law further provides that
anyone who "holds himself out" as a doctor is practicing medicine within the
12. See Defiance Milk Products Co. v. Du Mond, 309 N.Y. 537, 132 N.E.2d 829
(1956).
1. 13 A.D.2d 591, 212 N.Y.S.2d 884 (3d Dep't 1961).
2. N.Y. Educ. Law § 6514(2) (a).
3. N.Y. Educ. Law § 6514(2)(g).
